Literature DB >> 32840975

Second-generation BTK inhibitors hit the treatment bullseye with fewer off-target effects.

Maggie L Shaw.   

Abstract

Entities:  

Year:  2020        PMID： 32840975     DOI： 10.37765/ajmc.2020.88475

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN： 1088-0224            Impact factor:   2.229


× No keyword cloud information.
  5 in total

Review 1.  Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.

Authors:  Matt Shirley
Journal:  Target Oncol       Date:  2021-12-14       Impact factor: 4.493

2.  Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury.

Authors:  Chen Guang Yu; Vimala Bondada; Hina Iqbal; Kate L Moore; John C Gensel; Subbarao Bondada; James W Geddes
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 3.  Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.

Authors:  Garth E Ringheim; Matthew Wampole; Kinsi Oberoi
Journal:  Front Immunol       Date:  2021-11-03       Impact factor: 7.561

4.  Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.

Authors:  Chuanwei Yang; Yong Cui; Xiaohui Ren; Ming Li; Kefu Yu; Shaoping Shen; Haihui Jiang; Mingxiao Li; Xiaokang Zhang; Xuzhe Zhao; Qinghui Zhu; Song Lin
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

Review 5.  Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.

Authors:  Frédérique St-Pierre; Shuo Ma
Journal:  Blood Lymphat Cancer       Date:  2022-07-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.